- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Not listed
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- Up to 24 Months
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Presatovir, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Antiviral Prophylaxis, Respiratory Syncytial Virus Infection
- Interventions
- Placebo, SeVRSV Vaccine
- Other · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Respiratory Tract Infections
- Interventions
- Formulation A, Formulation B, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,235 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 40
- States / cities
- Mobile, Alabama • Anaheim, California • La Mesa, California + 30 more
- Conditions
- Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
- Interventions
- Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
- Diagnostic Test
- Lead sponsor
- Baebies, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,500 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Viral Pneumonia
- Interventions
- SNG001, Placebo
- Drug
- Lead sponsor
- Synairgen Research Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 22
- States / cities
- Sacramento, California • Torrance, California • Naples, Florida + 19 more
- Conditions
- RESPIRATORY SYNCYTIAL VIRUS (RSV)
- Interventions
- RSVpreF 120 µg, RSVpreF 60 µg
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Palo Alto, California • Rolling Hills Estates, California + 12 more
- Conditions
- Respiratory Viral Infections, Respiratory Syncytial Virus Infections, Parainfluenza Virus 3, Human
- Interventions
- MEDI-534
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 6 Months to 23 Months
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2010
- U.S. locations
- 30
- States / cities
- Conway, Arkansas • Little Rock, Arkansas • Aurora, Colorado + 25 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- mRNA-1345, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 0 Years to 40 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 22
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV vaccine (GSK3003891A) formulation 1, RSV vaccine (GSK3003891A) formulation 2, RSV vaccine (GSK3003891A) formulation 3, Placebo (Formulation buffer S9b)
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Newton, Kansas • Syracuse, New York • Ellensburg, Washington
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Clesrovimab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 1 Year
- Enrollment
- 3,632 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 51
- States / cities
- Dothan, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 45 more
- Conditions
- COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
- Interventions
- imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
- Device
- Lead sponsor
- The Geneva Foundation
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Fort Sam Houston, Texas
- Conditions
- Respiratory Tract Infection
- Interventions
- RSV Vaccine, Tdap, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 713 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 16
- States / cities
- Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Not listed
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 1 Month to 6 Months
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 59
- States / cities
- Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 50 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV ΔNS2/Δ1313/I1314L Vaccine, RSV 6120/ΔNS2/1030s Vaccine, RSV 276 Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 25 Months
- Enrollment
- 67 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 10 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 526 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 22 more
- Conditions
- Influenza, Respiratory Syncytial Viruses, Paramyxoviridae Infections, Coronavirus, Rhinovirus
- Interventions
- N95 Respirator, Medical/surgical mask
- Device
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 2,862 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 7
- States / cities
- Aurora, Colorado • Denver, Colorado • Washington D.C., District of Columbia + 3 more
- Conditions
- Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
- Interventions
- Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine, Placebo
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 777 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 19
- States / cities
- Long Beach, California • Hollywood, Florida • Port Orange, Florida + 14 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,459 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Phoenix, Arizona • North Hollywood, California + 13 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- ALS-008176, Placebo
- Drug
- Lead sponsor
- Alios Biopharma Inc.
- Industry
- Eligibility
- Up to 12 Months
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 14 more
- Conditions
- Respiratory Syncytial Virus, Human Metapneumovirus
- Interventions
- mRNA-1345, mRNA-1365, Placebo, Nimenrix
- Biological · Drug
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 5 Months to 24 Months
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Melrose Park, Illinois + 8 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSVpreF MDV, RSVpreF SDV
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 453 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 6
- States / cities
- South Miami, Florida • Stockbridge, Georgia • Idaho Falls, Idaho + 3 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Phosphate Buffer Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 11,850 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 51 more
- Conditions
- RSV Immunization
- Interventions
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 2,226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more